Cipla

{
  "main_header": {
    "sid": 597145,
    "name": "Cipla",
    "stock_name": "Cipla",
    "full_name": "Cipla Ltd.",
    "name_url": "stocks-analysis/cipla",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,465.75",
    "chg": -9.25,
    "chgp": "-0.63%",
    "dir": -1,
    "prev_price": "1,475.00",
    "mcapval": "118,409.93 Cr",
    "mcap": "Large Cap",
    "scripcode": 500087,
    "symbol": "CIPLA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE059A01026",
    "curr_date": "Aug 07, 12:44 PM",
    "curr_time": "12:45 PM",
    "last_traded_at": "Aug 07, 12:44 PM IST",
    "bse_nse_vol": "3.94 lacs",
    "exc_status": "Active",
    "traded_date": "Aug 07, 2026",
    "traded_date_str": "2026 08 07",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cipla-597145-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 33.29 vs Industry's 36.68: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-and-institutional-dynamics-in-2026-4141260",
        "imagepath": "",
        "date": "2026-08-07 09:21:23",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> currently trades at a P/E of 33.29, which is approximately 9.2% below the Pharmaceuticals & Biotechnology industry average of 36.68. This discount suggests that the market is valuing the company slightly more conservatively than its sector peers, despite Cipla’s status as a large-cap stock with a market capitalisation of ₹1,18,890.60 crores. The valuation gap may reflect concerns over growth prospects or competitive pressures, but it also implies a potential margin of safety relative to the sector’s average valuation. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"ctx\">Previously..."
      },
      {
        "title": "P/E at 32.73 vs Industry's 36.91: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-and-institutional-dynamics-in-2026-4139452",
        "imagepath": "",
        "date": "2026-08-06 09:20:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p>The current P/E of 32.73 for <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> represents a discount of approximately 11.3% relative to the sector average of 36.91. This valuation gap suggests that the market is pricing in either a more cautious outlook on Cipla’s earnings growth or perceives risks not fully reflected in the broader industry. Given the company’s large-cap status with a market capitalisation of ₹1,18,672.48 crores, such a discount is significant and invites a closer look at performance metrics and technical indicators to understand the underlying dynamics. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla..."
      },
      {
        "title": "Cipla Ltd. is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cipla-ltd-is-rated-hold-by-marketsmojo-4137756",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/CiplaLtd_mojoScore_4137756.png",
        "date": "2026-08-05 10:10:55",
        "description": "Cipla Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 July 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "P/E at 32.73 vs Industry's 36.85: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amid-mixed-market-performance-4137399",
        "imagepath": "",
        "date": "2026-08-05 09:20:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p>The current P/E of 32.73 for <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> contrasts with the sector average of 36.85, indicating the stock trades at a meaningful discount to its industry peers. This valuation differential suggests that investors may be pricing in either a more cautious outlook on Cipla’s near-term earnings growth or reflecting sector-wide headwinds that have not impacted Cipla as severely. The discount is particularly notable given Cipla’s status as a large-cap pharmaceutical company with a market capitalisation of ₹1,17,509.18 crores. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a>’s P/E..."
      },
      {
        "title": "Cipla Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-4134727",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/CiplaLtd_technicaldot_4134727.png",
        "date": "2026-08-04 08:05:37",
        "description": "Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a slight dip in price, the stock’s technical profile suggests a cautiously optimistic outlook, with recent upgrades in its Mojo Grade signalling improved investor sentiment."
      },
      {
        "title": "Cipla Ltd. Valuation Shifts Signal Price Attractiveness Change Amid Sector Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-valuation-shifts-signal-price-attractiveness-change-amid-sector-dynamics-4134350",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/CiplaLtd_valuationdot_4134350.png",
        "date": "2026-08-04 08:00:54",
        "description": "Cipla Ltd., a stalwart in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably in recent months, moving from fair to expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a recalibration of price attractiveness amid evolving market dynamics and peer comparisons."
      },
      {
        "title": "P/E at 33.25 vs Industry's 37.19: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-and-institutional-dynamics-amid-sectoral-shifts-4133110",
        "imagepath": "",
        "date": "2026-08-03 09:20:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amid Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 33.25, which is approximately 10.6% below the Pharmaceuticals & Biotechnology sector average of 37.19. This discount suggests that the market is pricing in either a more cautious outlook on Cipla's earnings growth or perceives relative risks compared to its peers. The sector's elevated P/E reflects optimism about growth prospects and innovation pipelines, yet Cipla's valuation indicates a more tempered investor sentiment. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a>'s sizeable market capitalisation of ₹1,18,413.97 crores conf..."
      },
      {
        "title": "Cipla Ltd Gains 4.40%: 2 Key Factors Driving the Week’s Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-gains-440-2-key-factors-driving-the-weeks-momentum-4131866",
        "imagepath": "",
        "date": "2026-08-01 17:00:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>27 Jul:</strong> Stock opens at Rs.1,409.85, marginally down -0.07% despite Sensex rally</p>\n                    <p><strong>28 Jul:</strong> Price rebounds +2.47% to Rs.1,444.65 amid steady volume</p>\n                    <p><strong>29 Jul:</strong> Significant open interest surge (+10.01%) in derivatives; stock gains +1.99% to Rs.1,473.45</p>\n                    <p><strong>30 Jul:</strong> Technical momentum shifts bullish; price dips slightly -0.51% to Rs.1,466.00</p>\n                    <p><strong>31 Jul:</strong> Week closes at Rs.1,472.95, up +0.47% on the day and +4.40% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div c..."
      },
      {
        "title": "P/E at 33.04 vs Industry's 37.11: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-and-institutional-dynamics-in-2026-4129731",
        "imagepath": "",
        "date": "2026-07-31 09:21:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> stands at 33.04, which is approximately 11% below the Pharmaceuticals & Biotechnology industry average of 37.11. This valuation discount suggests that the market is pricing in either a more cautious outlook on Cipla’s earnings growth or perceives higher risk relative to its peers. Given the sector’s overall strength, with an industry P/E elevated by growth expectations, Cipla’s lower multiple may reflect concerns about near-term earnings momentum or competitive pressures. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a>’s market capitalisation..."
      }
    ],
    "total": 1155,
    "sid": "597145",
    "stock_news_url": "https://www.marketsmojo.com/news/cipla-597145"
  },
  "announcements": [
    {
      "caption": "Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge Long Island New York USA",
      "datetime": "04-Aug-2026",
      "details": "Please find enclosed intimation.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
      "datetime": "31-Jul-2026",
      "details": "In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirments) Regulations 2015 we hereby notify that the Operations and Administrative Committee of the Company on 31st July 2026 has allotted 7850 fully paid up equity shares of INR 2 each pursuant to exercise of employee stock options/ stock appreciation rights under the Cipla ESOP Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company.",
      "source": "BSE"
    },
    {
      "caption": "Cipla Receives U.S. FDA Approval For Generic Advair Diskus®",
      "datetime": "27-Jul-2026",
      "details": "Please find enclosed disclosure",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has declared <strong>650%</strong> dividend, ex-date: 05 Jun 26",
          "dt": "2026-06-05",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has announced <strong>3:2</strong> bonus issue, ex-date: 24 Apr 06",
          "dt": "2006-04-24",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 33.29 vs Industry's 36.68: What the Data Shows for Cipla Ltd.

2026-08-07 09:21:23

Valuation Picture: Discount to Industry P/E

Cipla Ltd. currently trades at a P/E of 33.29, which is approximately 9.2% below the Pharmaceuticals & Biotechnology industry average of 36.68. This discount suggests that the market is valuing the company slightly more conservatively than its sector peers, despite Cipla’s status as a large-cap stock with a market capitalisation of ₹1,18,890.60 crores. The valuation gap may reflect concerns over growth prospects or competitive pressures, but it also implies a potential margin of safety relative to the sector’s average valuation. Previously...

Read full news article

P/E at 32.73 vs Industry's 36.91: What the Data Shows for Cipla Ltd.

2026-08-06 09:20:50

Valuation Picture: Discount to Industry P/E

The current P/E of 32.73 for Cipla Ltd. represents a discount of approximately 11.3% relative to the sector average of 36.91. This valuation gap suggests that the market is pricing in either a more cautious outlook on Cipla’s earnings growth or perceives risks not fully reflected in the broader industry. Given the company’s large-cap status with a market capitalisation of ₹1,18,672.48 crores, such a discount is significant and invites a closer look at performance metrics and technical indicators to understand the underlying dynamics. Cipla...

Read full news article

Cipla Ltd. is Rated Hold by MarketsMOJO

2026-08-05 10:10:55

Cipla Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 July 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

P/E at 32.73 vs Industry's 36.85: What the Data Shows for Cipla Ltd.

2026-08-05 09:20:37

Valuation Picture: Discount to Industry P/E

The current P/E of 32.73 for Cipla Ltd. contrasts with the sector average of 36.85, indicating the stock trades at a meaningful discount to its industry peers. This valuation differential suggests that investors may be pricing in either a more cautious outlook on Cipla’s near-term earnings growth or reflecting sector-wide headwinds that have not impacted Cipla as severely. The discount is particularly notable given Cipla’s status as a large-cap pharmaceutical company with a market capitalisation of ₹1,17,509.18 crores. Cipla Ltd.’s P/E...

Read full news article

Cipla Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals

2026-08-04 08:05:37

Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a slight dip in price, the stock’s technical profile suggests a cautiously optimistic outlook, with recent upgrades in its Mojo Grade signalling improved investor sentiment.

Read full news article

Cipla Ltd. Valuation Shifts Signal Price Attractiveness Change Amid Sector Dynamics

2026-08-04 08:00:54

Cipla Ltd., a stalwart in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably in recent months, moving from fair to expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a recalibration of price attractiveness amid evolving market dynamics and peer comparisons.

Read full news article

P/E at 33.25 vs Industry's 37.19: What the Data Shows for Cipla Ltd.

2026-08-03 09:20:41

Valuation Picture: Discount Amid Sector Premiums

Cipla Ltd. trades at a P/E multiple of 33.25, which is approximately 10.6% below the Pharmaceuticals & Biotechnology sector average of 37.19. This discount suggests that the market is pricing in either a more cautious outlook on Cipla's earnings growth or perceives relative risks compared to its peers. The sector's elevated P/E reflects optimism about growth prospects and innovation pipelines, yet Cipla's valuation indicates a more tempered investor sentiment. Cipla Ltd.'s sizeable market capitalisation of ₹1,18,413.97 crores conf...

Read full news article

Cipla Ltd Gains 4.40%: 2 Key Factors Driving the Week’s Momentum

2026-08-01 17:00:05

Key Events This Week

27 Jul: Stock opens at Rs.1,409.85, marginally down -0.07% despite Sensex rally

28 Jul: Price rebounds +2.47% to Rs.1,444.65 amid steady volume

29 Jul: Significant open interest surge (+10.01%) in derivatives; stock gains +1.99% to Rs.1,473.45

30 Jul: Technical momentum shifts bullish; price dips slightly -0.51% to Rs.1,466.00

31 Jul: Week closes at Rs.1,472.95, up +0.47% on the day and +4.40% for the week

Read full news article

P/E at 33.04 vs Industry's 37.11: What the Data Shows for Cipla Ltd.

2026-07-31 09:21:04

Valuation Picture: Discount to Industry P/E

The current P/E of Cipla Ltd. stands at 33.04, which is approximately 11% below the Pharmaceuticals & Biotechnology industry average of 37.11. This valuation discount suggests that the market is pricing in either a more cautious outlook on Cipla’s earnings growth or perceives higher risk relative to its peers. Given the sector’s overall strength, with an industry P/E elevated by growth expectations, Cipla’s lower multiple may reflect concerns about near-term earnings momentum or competitive pressures. Cipla Ltd.’s market capitalisation...

Read full news article

View All News